Thursday 25th February 2021
|Text too small?|
In November 2020 Gentrack Group Limited (NZX/ASX: GTK) (“Gentrack”) advised that it expected that the full year EBITDA run rate for FY21 would be well below that of the H2 FY20 run rate and that FY21 profitability may be reduced closer to break-even depending on the levels of future product investment and other factors.
Gentrack now provides the following outlook update:
•FY21 revenues are expected to be close to or slightly ahead of FY20 revenues of $100.5m
•FY21 EBITDA is expected to be around $5m on the basis that research and development (R&D) costs are expensed
•Incremental R&D costs are expected to be ~$3m/quarter from Q3 FY21
•The company expects to be net cashflow positive in FY21, building on the $16.8m of net cash reported at 30th September 2020.
Profit and cashflow are expected to be weighted to H1 FY21 given the incremental R&D spend forecast for H2.
Please see the link below for details:
No comments yet
NZME Limited (NZX: NZM) NZ Markets Disciplinary Tribunal Censures
Rua Bioscience Limited (NZX: RUA) Announces CCO with Global Pharma Experience
Cannasouth Limited (NZX: CBD) Supply Activity Added to Cannasouth Commercial Licence
Skellerup Holdings Limited (NZX: SKL) Upgrades FY21 Earnings Guidance
Napier Port Holdings Limited (NZX: NPH) 2021 Earnings Guidance Update
Comvita Limited (NZX: CVT) Full Year Guidance Update
Scott Technology Limited (NZX: SCT) Meat Industry Contract Win
PaySauce Limited (NZX: PYS) Quarterly Market Update
NZ Windfarms Limited (NZX: NWF) Agrees a New VVFPA for Q1 2022 to Q3 2022
Harmoney Corp Limited (NZX: HMY) 3Q21 Trading Update